Navigation Links
Sanovas Awarded Patent for Abrading Balloon Catheter for Extravasated Drug Delivery
Date:12/3/2013

SAUSALITO, Calif., Dec. 3, 2013 /PRNewswire/ -- Sanovas, Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies announced today that the United States Patent and Trademark Office issued patent # 8,597,239 for the company's Abrading Balloon Catheter for Extravasated Drug Delivery.

The Abrading Balloon Catheter for Extravasated Drug Delivery is a multi-lumen balloon catheter that features abrasive outer surfaces upon the substrate of the balloons that are intended to abrade tissue and stimulate cellular function to optimize the osmotic uptake of therapeutic agents into target tissues. The device temporarily occludes a specific region to create a localized treatment chamber for the focal and/or circumferential delivery of various types of therapeutic agents to treat a variety of disease states via the company's patented methods of extravasated drug delivery.

"We believe clinicians will appreciate the broad utility of this asset," related Sanovas CEO, Larry Gerrans. "This will be an intelligent and effective device intended to significantly improve localized, precision therapies. It is analogous to the Swiss Army Knife of Drug Delivery Catheters."

The technology measures and modulates the volumetric pressure gradients of therapeutic agent(s) within the treatment chamber(s) to perfuse the agent(s) across the tissue membrane enabling controlled delivery of the agents directly to target tissues. The system affords clinicians substantial procedural control, including the ability to select the therapeutic agent(s) of their choice and to continuously circulate, irrigate, abrade, extravasate and evacuate the treatment site while mitigating the systemic release of the agent.

"This patent is a significant cornerstone to the company's NanoVas™ portfolio of Interventional Drug Delivery Solutions," said Gerrans. "These tools are vital to the continued growth and promise of Personalized Medicine."  

Sanovas expects to commercialize the technology in coordination with its various partners to meet unmet clinical needs in Pulmonology, Cardiology, Neurology and Uro-Gynecology.

About Sanovas

Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways.

Contact for Sanovas:

Steve Goldsmith
Vice President Marketing
sgoldsmith@sanovas.com
(415) 729- 9391 ext. 1023


'/>"/>
SOURCE Sanovas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanovas Launches Next Generation Surgical Imaging Technology
2. Sanovas Fills Corporate Bench with Industry Veterans In Clinical, Regulatory and Finance
3. Sanovas Forms Scientific Advisory Board to Support Development of Lung Cancer Technology
4. WPPS GO Team Awarded Tums and Eno Global Account by GlaxoSmithKline
5. T1D Exchange Awarded $2.8M Grant by JDRF to Study Metformin and Type 1 Diabetes
6. NanoBio Awarded Up To $10 Million In NIH Funding To Develop A Pandemic Influenza Vaccine
7. Pfenex Inc. awarded a subcontract by Leidos to develop a scalable cGMP production process for a second key malaria antigen
8. AMRI Awarded Development and Manufacture Contract from the UK Government
9. Numotion Awarded Best Complex Rehab Provider
10. Isis Pharmaceuticals Stanley Crooke Awarded Corporate Forums Director of the Year
11. Access Pharmaceuticals Awarded Second European Patent for MuGard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... has awarded grants totaling more than $2 million to 16 ... Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from ... Uniformed Services University of the Health Sciences in ... announced last night during a reception at the International Society ... Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... Fresh Wave® ... Liquid eco-friendly odor-control solution for colleges and universities at the APPA 2017 ... effectively eliminate severe cannabis and tobacco smoke odors without the use of harsh chemicals, ...
(Date:7/21/2017)... ... 2017 , ... Hospital M&A activity slowed in the second quarter of 2017, ... rose to 23 in the second quarter, up 15% from the 20 publicly announced ... deals in the year-ago second quarter. Only four of the transactions disclosed a purchase ...
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
Breaking Medicine News(10 mins):